TMCnet News
Electronic Clinical Outcome Assessment Solution Analysis Report 2024: Global Market to Reach $3.9 Billion by 2029, Driven by Growing Outsourcing of Clinical Trial Processes to CROsDUBLIN, March 19, 2024 /PRNewswire/ -- The "Global Electronic Clinical Outcome Assessment (eCOA) Solution Market by Modality (Wearable, Mobile, BYOD), Type (PRO, CLINRO, OBSRO, PERFO), Use ([Clinical trial: Onco, Rare, Mental Health], RWE, Registery), End-user, and Region - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.  The electronic clinical outcome assessment (eCOA) solutions market is projected to reach USD 3.9 billion by 2029 from USD 1.8 billion in 2024, at a CAGR 16.6% The growing inclination towards digital data collection and analysis, an escalating need for economical data collection solutions, and the increasing integration of connected devices in healthcare institutions are the factors that will drive the growth of this market. On the other hand, the sensitivity of patient health data requires robust security measures. Concerns about data breaches, unauthorized access, or cybersecurity threats may impede the adoption of eCOA solutions to a certain extent over the forecast period. In 2022, Asia-Pacific was expected to register the highest growth for electronic clinical outcome assessment (eCOA) solutions systems in the forecast period. Factors such as increasing healthcare expenditure, developing healthcare infrastructure, rising demand for digital solutions in healthcare sector, large patient population, increasing focus on patient-centric care and the need for better data collection and analysis are expected to drive the growth of the electronic clinical outcome assessment (eCOA) solutions market in the Asia-Pacific. Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market. The BYOD (bring your own device) model segment is estimated to hold the major share in 2023, by type of wearable, mobile and other devices The wearable, mobile and other devices market is bifurcated into BYOD (bring your own device) model, provisioned device model, and hybrid model. The BYOD model segment accounted for the largest market share during the forecast period. The growth of BYOD (Bring Your Own Device) adoption is driven by cost-effectiveness, as it eliminates the need for sponsors to manage dedicated devices, lowering trial costs. Patient familiarity with their own devices enhances user-friendliness, boosting engagement and data quality, while increasing accessibility for geographically dispersed and resource-limited patients, aligning with decentralized trials. Additionally, technological advancements in secure data encryption address security concerns, and evolving regulations favor secure BYOD implementation in certain regions, positioning it as a cost-efficient, patient-centric approach in clinical trials. Clinical trials segment is estimated to hold the largest share of electronic clnical outcome assessment (eCOA) solutions market, by application Based on application, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into clinical trials, observational studies and real-world evidence (RWE) generation, patient management and registries, and other applications. The clinical trials segment is expected to hold the largest share during the forecast period. The rise of eCOA (Electronic Clinical Outcome Assessment) in clinical trials is driven by a myriad of advantages: heightened data quality achieved through real-time capture and minimized transcription errors, enhanced patient engagement facilitated by user-friendly platforms and improved data ownership, and increased trial efficiency through streamlined data collection and accelerated analysis. This results in superior-quality studies, increased patient satisfaction, and expedited drug development, positioning eCOA as the emerging gold standard for a more efficient, patient-centric future in clinical research. Electronic Observer-Reported Outcomes (EOBSRO) segment is expected to register highest growth in the forecast period, by product type segment Based on product type, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into electronic patient-reported outcomes (EPRO), Electronic Clinician-reported outcomes (ECLINRO), electronic observer-reported outcomes (EOBSRO), and Electronic performance-reported outcomes (EPERFO). In 2023, the electronic observer-reported outcomes (EOBSRO) segment segment is expected to register highest growth in the forecast period. Observer-reported outcomes (ObsRO) play a crucial role in gathering real-world evidence outside controlled trial settings, informing post-market research and regulatory decisions. Effective patient monitoring in decentralized trials, improved data quality, availability of holistic picture of patient experience and treatment response are some of the factors that contribute to the growth of the segment. Premium Insights
Case Study Analysis
Market Dynamics Drivers
Restraints
Opportunities
Challenges
Overview of Key Industry Trends
Technology Analysis Key Technologies
Complementary Technologies
Adjacent Technologies
Company Profiles Key Players
Other Players
For more information about this report visit https://www.researchandmarkets.com/r/yjm0vk About ResearchAndMarkets.com Media Contact: Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets 
|
View original content: